Evidence level: C
斗型纹频率与白血病风险之间若真存在因果链,必须连过两道统计闸门——共定位排除「同区不同因」,孟德尔随机化排除「同因不同果」——而这一双方法联合验证在皮纹学领域至今尚未被执行。
传统掌纹文化把掌上纹路当作体质与命运的印记;现代皮纹学(dermatoglyphics)延续了其中最可检验的那部分直觉:指纹嵴线在孕期约 13–19 周成形,此后终生不变,等于把「当时宫内环境与早期发育基因」压成了一张不可篡改的底片。正因如此,医学界很早就试图在皮纹里找疾病的早期窗口:有小样本研究报告儿童急性淋巴细胞白血病患者的指纹型分布与对照组存在差异(PMID 20838939),掌部皮纹指标的初步研究也提示类似方向(PMID 21420648);近年还有指纹特征与癌症易感性关系的汇总讨论(PMID 36915473)。但这些观察性研究的共同短板是:样本小、指标粗、完全无法区分「皮纹和白血病真有共同根源」与「统计上的巧合」。
机制层面确实存在一条值得追查的通道。指纹是涡是箕,由肢体发育期的基因表达梯度决定——2022 年 Cell 上的指纹模式全基因组研究把 WNT/BMP 信号通路锁定为斗型纹与箕型纹分化的核心(PMID 34995520)。而造血系统这边,位于 3q26 的 EVI1 是造血干细胞调控的经典多效基因,其异常激活在急性髓系白血病中驱动耐药与不良预后,近期研究还在揭示 EVI1 依赖性耐药的具体机制(PMID 42241446)。如果皮纹 GWAS 与白血病 GWAS 的关联信号恰好落在同一基因组区域,一个自然的假设是:同一个(或同一组)因果变异,既参与胚胎期肢端发育,也参与造血调控——皮纹只是这条共享发育通道露在体表的刻度。
这正是双方法联合检验要解决的问题,两道闸门缺一不可。第一道是共定位(colocalization,coloc):用贝叶斯方法检验两个性状在该区域的关联是否由同一个因果变异驱动,以 PP.H4 后验概率为判据,通常要求超过 0.8 才算通过(PMID 24830394)。它排除的是「同区不同因」——两个真关联因为连锁不平衡挤在同一个区域、实则各管各的那类假阳性。第二道是双样本孟德尔随机化:用皮纹 GWAS 的显著位点作为遗传工具变量,估计对白血病风险的因果效应,主判据用逆方差加权,辅以加权中位数和 MR-Egger 检验多效性偏倚(PMID 26050253)。它排除的是「同因不同果」——共享的混杂或反向因果把两个性状绑在一起。coloc 通过而 MR 失败,结论是「共享发育基因」而非「皮纹预测白血病」;两者都通过,「皮纹-血液系统疾病」这条链才算真正闭合。
这个检验至今没有落地,瓶颈在白血病侧的数据。皮纹表型侧已有了像样的 GWAS 汇总统计量(PMID 34995520),但白血病易感性 GWAS 的样本量仍偏小:儿童 TCF3-PBX1 亚型全基因组研究定位的易感位点有限(PMID 32882024),2025 年的儿童 B-ALL 跨祖源 GWAS 虽然补充了非洲祖源特异位点,可提取的独立工具变量依旧不多(PMID 41125582)。工具变量少,MR 检验功效打折;区域信号稀疏,coloc 判据也容易落在灰色地带。这正是本课题把「双方法 + 与神经精神通道结果对照」写成执行方案的原因:同样的皮纹 GWAS,与精神分裂等神经通道的共定位证据相对成熟,若 EVI1/3q26 血液通道的 coloc 与 MR 结果同神经通道形成方向或强度上的系统差异,本身就是一个有信息量的分层证据。
判读框架要提前说死,免得事后挑结果:coloc 与 MR 双过,升级为 A 级候选、写入发育共因证据;coloc 过而 MR 不过,结论只能写「同一基因影响两种性状」,皮纹不得表述为风险预测标志;双败,则现有皮纹-白血病观察性关联大概率是小样本与人群结构造成的假象。无论落在哪一格,这都比单纯再做一组病例对照更接近真相。
证据与局限
已验证: 指纹形态由 WNT/BMP 等发育基因决定,有指纹模式 GWAS 支撑(PMID 34995520);EVI1 异常在急性髓系白血病中有明确功能与临床意义(PMID 42241446);coloc 与双样本 MR 方法本身成熟、判据清晰(PMID 24830394, 26050253)。
部分验证: 皮纹与儿童白血病存在观察性关联的初步报告,但均为小样本、指标粗糙、未系统校正人群结构(PMID 20838939, 21420648, 36915473)。
待验证: 斗型纹 GWAS × 白血病 GWAS 的 coloc PP.H4 判定与双样本 MR(IVW/加权中位数/MR-Egger)联合检验——这是判定「皮纹-血液系统疾病」完整链条的裁决性实验,目前尚未有任何团队执行。该主题尚未进入 L1 对应网络,属于初步探索。
相关阅读
L1 网络状态:该主题尚未进入 L1 对应网络——EDGE_TABLE_science-yixue.md 中 grep「皮纹/斗型纹/EVI1/dermatoglyph/白血病」零命中(2026-11-08 经 N200 核实),证据等级仅可标 C。
证据等级: C
参考文献: PMID 34995520, PMID 42241446, PMID 24830394, PMID 26050253, PMID 20838939, PMID 21420648, PMID 36915473, PMID 32882024, PMID 41125582
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
EVI1 Pleiotropic Channel Dual-Mechanism Validation: coloc Co-localization + Two-Sample Mendelian Randomization Joint Test of Dactyloprint Frequency and Leukemia Risk Association…
Evidence level: C
If a causal chain truly exists between whorl frequency and leukemia risk, it must pass two statistical gates—coloc to exclude “same region, different cause,” and Mendelian randomization (MR) to exclude “same cause, different effect”—yet this dual-method joint validation has not yet been executed in the field of dermatoglyphics.
Traditional palmistry culture treats palm lines as imprints of constitution and fate; modern dermatoglyphics extends the most testable part of this intuition: fingerprint ridges form around 13–19 weeks of gestation and remain unchanged thereafter, effectively compressing “in-utero environment and early developmental genes” into an unalterable negative. For this reason, the medical community has long attempted to find early disease windows within dermatoglyphics: small-sample reports found differences in fingerprint pattern distribution between pediatric acute lymphoblastic leukemia patients and controls (PMID 20838939), preliminary studies of palm dermatoglyphic indicators also point in a similar direction (PMID 2140648); recent discussions have summarized the relationship between fingerprint characteristics and cancer susceptibility (PMID 36915473). However, the common shortcoming of these observational studies is: small sample size, coarse indicators, and complete inability to distinguish “dermatoglyphics and leukemia share a common root” from “statistical coincidence.”
Mechanistically, there indeed exists a channel worth investigating. Fingertips are whorls or loops, determined by gene expression gradients during limb development—the 2022 Cell whole-genome study of fingerprint patterns locked the WNT/BMP signaling pathway as the core for whorl versus loop differentiation (PMID 34995520). On the hematopoietic side, EVI1 located at 3q26 is a classic pleiotropic gene regulating hematopoietic stem cells; its aberrant activation drives drug resistance and poor prognosis in acute myeloid leukemia, with recent research also revealing specific mechanisms of EVI1-dependent resistance (PMID 42241446). If the association signals of dermatoglyphic GWAS and leukemia GWAS coincidentally fall in the same genomic region, a natural hypothesis arises: the same (or set of) causal variants participate both in embryonic limb development and hematopoietic regulation—the dermatoglyphic pattern merely represents the surface-scale of this shared developmental channel.
This is precisely what the dual-method joint test aims to resolve; both gates are indispensable. The first is colocalization (coloc): using Bayesian methods to test whether the association of two traits in this region is driven by the same causal variant, with PP.H4 posterior probability as the criterion—typically requiring >0.8 to pass (PMID 24830394). This excludes “same region, different cause”—false positives where two true associations are squeezed into the same region due to linkage disequilibrium but actually regulate different pathways. The second is two-sample Mendelian randomization: using significant loci from the dermatoglyphic GWAS as genetic instrumental variables to estimate the causal effect on leukemia risk, with inverse-variance weighting as the primary criterion, supplemented by weighted median and MR-Egger tests for pleiotropic bias (PMID 26050253). This excludes “same cause, different effect”—shared confounding or reverse causality binding the two traits together. If coloc passes but MR fails, the conclusion is “shared developmental gene” rather than “dermatoglyphics predict leukemia”; only if both pass does the “dermatoglyphics-hematopoietic disease” chain truly close.
This test has not yet been implemented; the bottleneck lies in leukemia-side data. The dermatoglyphic phenotype side already has decent GWAS summary statistics (PMID 34995520), but leukemia susceptibility GWAS sample size remains too small: the pediatric TCF3-PBX1 subtype whole-genome study identified limited susceptibility loci (PMID 32882024), and while the 2025 pediatric B-ALL cross-ancestry GWAS supplemented African-specific loci, the number of extractable independent instrumental variables remains insufficient (PMID 41155582). Fewer instrumental variables reduce MR test power; sparse regional signals make coloc criteria easily fall into gray areas. This is precisely why this project writes out the execution plan as “dual-method + comparison with neuro-psychiatric pathway results”: using the same dermatoglyphic GWAS, colocalization evidence with schizophrenia and other neuro pathways is relatively mature; if the EVI1/3q26 blood pathway coloc and MR results show systematic differences in direction or intensity compared to the neuro pathway, this itself constitutes informative stratified evidence.
The interpretation framework must be fixed in advance to avoid cherry-picking results later: coloc and MR both pass → upgrade to A-level candidate, write as developmental common cause evidence; coloc passes but MR fails → conclusion can only state “same gene affects two traits,” dermatoglyphics cannot be expressed as risk prediction markers; both fail → existing dermatoglyphic-leukemia observational associations are likely artifacts of small sample size and population structure. Regardless of which cell it falls into, this is closer to truth than simply conducting another case-control study.
Evidence and Limitations
Verified: Fingerprint morphology is determined by developmental genes such as WNT/BMP, supported by fingerprint pattern GWAS (PMID 34995520); EVI1 abnormalities have clear functional and clinical significance in acute myeloid leukemia (PMID 42241446); coloc and two-sample MR methods are mature with clear criteria (PMID 24830394, 26050253).
Partially Verified: Preliminary reports show an observational association between dermatoglyphics and childhood leukemia, but these are based on small samples, crude indicators, and lack systematic correction for population structure (PMID 20838939, 21420648, 36915473).
Pending Verification: coloc PP.H4 determination combined with two-sample MR (IVW/weighted median/MR-Egger) analysis of fight-type ridge GWAS × leukemia GWAS—this constitutes the decisive experiment for establishing the complete chain linking “dermatoglyphics-hematopoietic system disease.” This topic has not yet entered the L1 corresponding network and remains in preliminary exploration.
Related Reading
- PRS Mediation Proportion Estimation for Dermatoglyph–Disease Associations: Variance Decomposition of Intrauterine Environmental Imprinting Pathways vs. Genetic Common Cause Pathways
- Sibling Pair Discordant Testing for the Risk of Low PRS × Dermatoglyphic Anomaly
- Research Pool
L1 Network Status: This topic has not yet entered the corresponding L1 network. Zero hits were found in
EDGE_TABLE_science-yixue.mdfor the terms “dermatoglyph/whorl pattern/EVI1/dermatoglyph/leukemia” (verified via N200 on 2026-11-08). Consequently, the evidence level can only be designated as C.Evidence Level: C
References: PMID 34995520, PMID 42241446, PMID 24830394, PMID 26050253, PMID 20838939, PMID 21420648, PMID 36915473, PMID 32882024, PMID 41125582
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply